Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/pds.5029 http://scihub22266oqcxt.onion/10.1002/pds.5029 32369865!ä!32369865 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacoepidemiol+Drug+Saf 2020 ; 29 (8): 825-831 Nephropedia Template TP {{tp|p=32369865|t=2020. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic |pdf=|usr=}}{{32369865}} gab.com Text Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic JO: Pharmacoepidemiol Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=32369865 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic has triggered several hypotheses regarding use of specific medicines and risk of infection as well as prognosis. Under these unique circumstances, rapid answers require quick engagement in data collection and analyses; however, appropriate design and conduct of pharmacoepidemiologic studies are needed to generate valid and reliable evidence. In this paper, endorsed by the International Society for Pharmacoepidemiology, we provide methodological considerations for the conduct of pharmacoepidemiological studies in relation to the pandemic across eight domains: (1) timeliness of evidence, including the need to prioritise some questions over others in the acute phase of the pandemic; (2) the need to align observational and interventional research on efficacy; (3) the specific challenges related to "real-time epidemiology" during an ongoing pandemic; (4) what design to use to answer a specific question; (5) considerations on the definition of exposures; (6) what covariates to collect; (7) considerations on the definition of outcomes; and (8) the need for transparent reporting. Twit Text FOAVip Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic ????Pharmacoepidemiol Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=32369865 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32369865 #FOAvip English Wikipedia <ref>{{Cite pmid|32369865}}</ref> Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic #MMPMID32369865 Pottegard A; Kurz X; Moore N; Christiansen CF; Klungel O Pharmacoepidemiol Drug Saf 2020[Aug]; 29 (8): 825-831 PMID32369865show ga The coronavirus disease 2019 (COVID-19) pandemic has triggered several hypotheses regarding use of specific medicines and risk of infection as well as prognosis. Under these unique circumstances, rapid answers require quick engagement in data collection and analyses; however, appropriate design and conduct of pharmacoepidemiologic studies are needed to generate valid and reliable evidence. In this paper, endorsed by the International Society for Pharmacoepidemiology, we provide methodological considerations for the conduct of pharmacoepidemiological studies in relation to the pandemic across eight domains: (1) timeliness of evidence, including the need to prioritise some questions over others in the acute phase of the pandemic; (2) the need to align observational and interventional research on efficacy; (3) the specific challenges related to "real-time epidemiology" during an ongoing pandemic; (4) what design to use to answer a specific question; (5) considerations on the definition of exposures; (6) what covariates to collect; (7) considerations on the definition of outcomes; and (8) the need for transparent reporting. |*Research Design[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*epidemiology[MESH] |Data Collection/methods[MESH] |Humans[MESH] |Pandemics[MESH] |Pharmacoepidemiology/*organization & administration/standards[MESH] |Pneumonia, Viral/*epidemiology[MESH] |SARS-CoV-2[MESH]Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing